Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma

Noh, Byeong-Joo; Kwak, Jae Young; Eom, Dae-Woon

doi:10.1186/s12885-020-6553-9

BMC Cancer

Table 4 Univariate analysis (Log-rank test) for overall survival

From: Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma

Parameters		Mean Survival (Months)	Confidence Interval (95%)		P
Parameters		Mean Survival (Months)	Lower	Upper	P
Age	Less than 67 yrs	116.5	107.2	125.8	< 0.001*
Age	More than 67 yrs	87.6	60.3	85.9
Sex	Male	103.9	95.7	112.2	0.330
Sex	Female	94.1	83.3	105.0
Size	Less than 4.9 cm	92.6	84.1	101.0	0.109
Size	More than 4.9 cm	107.2	97.6	116.8
Location	Ascending	100.2	84.6	115.7	0.716
	Transverse to sigmoid	98.9	90.3	107.6
	Rectum	95.8	83.4	108.1
Histologic type	Intestinal type	101.1	94.4	107.8	0.856
Histologic type	Mucinous type	82.0	55.6	108.3
Differentiation	Well	106.4	90.5	122.2	0.117
	Moderately	99.8	92.5	107.0
	Poorly	88.4	61.1	115.7
Lymphovascular invasion	Absence	109.8	101.7	117.8	< 0.001*
Lymphovascular invasion	Presence	77.3	66.6	88.0
Perineural invasion	Absence	94.9	87.2	102.6	0.003*
Perineural invasion	Presence	68.0	52.1	84.0
pT category	pT1–2	112.2	99.9	124.4	< 0.001*
	pT3	100.3	92.6	108.1
	pT4	73.8	54.7	92.8
Lymph node metastasis	Absence	113.3	104.6	122.0	< 0.001*
Lymph node metastasis	Presence	84.9	75.2	94.6
Stage	I	100.9	88.4	113.4	< 0.001*
	II	113.8	103.8	123.7
	III	88.9	78.7	99.1
	IV	37.2	19.7	54.6
Deficient mismatch repair	Absence	98.9	92.0	105.8	0.014*
Deficient mismatch repair	Presence	126.8	105.8	147.8
Chemo- or radiotherapy	Absence	83.3	72.1	94.4	< 0.001*
Chemo- or radiotherapy	Presence	109.5	101.7	117.4
Local recurrence	Absence	147.6	142.1	153.2	< 0.001*
Local recurrence	Presence	42.2	37.4	46.9
PD-1 expression	Low	93.2	84.5	101.9	0.001*
PD-1 expression	High	109.2	99.9	118.5
CD8 expression	Low	92.4	83.9	101.0	0.002*
CD8 expression	High	114.8	104.4	125.2
PD-L1 expression	Negative	94.9	86.3	103.4	0.007*
PD-L1 expression	Positive	107.1	97.7	116.6
Tumour microenvironmentimmune type	Type I (PD-L1+/CD8H)	122.1	110.2	133.9	< 0.001*
	Type III (PD-L1+/CD8L) & Type IV (PD-L1−/CD8H)	96.9	85.8	108.0
	Type II (PD-L1−/CD8L)	92.4	82.2	102.6

Cases with no clinical information or for which the data are not assessable due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues are excluded in statistical analyses

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com